E2F inhibitors (TopoTarget/InhibOx)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameE2F inhibitors (TopoTarget/InhibOx)
Drug Alias NameE2F inhibitors (Prolifix/Chugai)E2F inhibitors (Prolifix/Chugai/Lilly)E2F inhibitors (Prolifix)
ClassificationBiologics
Mechanisms of ActionOncogene proteins inhibitorsE2F transcription factors inhibitors
TargetsOncogene proteinsE2F transcription factors
Therapy Area/IndicationsPsoriasisCoronary RestenosisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomJapan
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTopoTarget UK Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOxford Drug DesignTopoTarget UK LtdChugai Pharmaceutical Co Ltd +[4] 
Active IndicationsN/A
Inactive IndicationsPsoriasisCoronary RestenosisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A